Related references
Note: Only part of the references are listed.Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT
Nickpreet Singh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
William S. Weintraub et al.
JAMA NETWORK OPEN (2022)
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Prakriti Gaba et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients
William E. Boden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
Benjamin E. Peterson et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)
Impact of Icosapent Ethyl on Cardiovascular Risk Recuction in Patients With Heart Failure in REDUCE-IT
Senthil Selvaraj et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
Matthew J. Budoff et al.
CARDIOVASCULAR RESEARCH (2021)
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
Brian Olshansky et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Reduction in Revascularization With Icosapent Ethyl Insights From REDUCE-IT Revascularization Analyses
Benjamin E. Peterson et al.
CIRCULATION (2021)
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction A Randomized, Controlled Trial
Are Annesonn Kalstad et al.
CIRCULATION (2021)
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
Subodh Verma et al.
CIRCULATION (2021)
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Arjun Majithia et al.
CIRCULATION (2021)
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
Gabriel Steg et al.
EUROPEAN HEART JOURNAL (2021)
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Prakriti Gaba et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability
Samuel C. R. Sherratt et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2021)
Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction
R. Preston Mason et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
Salim S. Virani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization
Ram D. Bhatt et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2021)
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
Andrew Kosmopoulos et al.
ISCIENCE (2021)
Meta-Analysis of Contemporary Trials of Omega-3 Fatty Acids Containing Both Eicosapentaenoic and Docosahexaenoic Acids
Safi U. Khan et al.
ECLINICALMEDICINE (2021)
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Safi U. Khan et al.
ECLINICALMEDICINE (2021)
EPA and DHA containing phospholipids have contrasting effects on membrane structure
Samuel C. R. Sherratt et al.
JOURNAL OF LIPID RESEARCH (2021)
REDUCE-IT USA Results From the 3146 Patients Randomized in the United States
Deepak L. Bhatt et al.
CIRCULATION (2020)
Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography
Suvasini Lakshmanan et al.
CARDIOVASCULAR RESEARCH (2020)
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
William E. Boden et al.
EUROPEAN HEART JOURNAL (2020)
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
R. Preston Mason et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus A Scientific Statement From the American Heart Association
Suzanne Arnold et al.
CIRCULATION (2020)
Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction
Suzanne Arnold et al.
JAMA NETWORK OPEN (2020)
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Xiaowen Wang et al.
CURRENT DIABETES REPORTS (2020)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Matthew J. Budoff et al.
EUROPEAN HEART JOURNAL (2020)
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Brian Olshansky et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque
Gregg W. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis
Marcello Arca et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction
William E. Boden et al.
FUTURE CARDIOLOGY (2020)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Fabien Picard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!
Deepak L. Bhatt
EUROPEAN HEART JOURNAL (2019)
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient JACC State-of-the-Art Review
Armin Arbab-Zadeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
REPLY: Ischemic Event Reduction and Triglycerides
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
R. Preston Mason et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Tetsu Watanabe et al.
JOURNAL OF CARDIOLOGY (2017)
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Jonathan D. Newman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Deepak L. Bhatt et al.
CLINICAL CARDIOLOGY (2017)
Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
Ryo Nishio et al.
ATHEROSCLEROSIS (2014)
Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-Rationale and design
Tetsu Watanabe et al.
JOURNAL OF CARDIOLOGY (2014)
A Prospective Natural-History Study of Coronary Atherosclerosis.
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito et al.
ATHEROSCLEROSIS (2008)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
